Articles from Dispatch Bio

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced the presentation of new preclinical data supporting its SEND (Synthetic Efficacy eNableD) T cell armoring strategy at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, taking place May 11–15, 2026, in Boston. The data will be presented in a poster entitled, “SEND – A T cell armoring strategy that incorporates simultaneous signaling through multiple pathways for optimized safety and efficacy via novel cell state,” during a poster session on Thursday, May 14, from 5:00–6:30 p.m.

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, and CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, today announced a clinical collaboration to conduct a Phase 1 trial in China, planned to begin in 2026.

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for DISP-10, enabling the initiation of a Phase 1 clinical study in patients with solid tumors.

Dispatch Bio, a biotechnology company developing a universal treatment for solid tumors, today announced preclinical data supporting its first therapeutic program planned to enter the clinic, DISP-10, and its first-in-class Flare platform, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting.

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with Bristol Myers Squibb (“BMS”) to support the development of Dispatch’s DISP-10 program. Under the agreement, BMS will provide idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T therapy, for use in Dispatch’s first U.S. Phase 1 trial, expected to initiate in 2026.

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform, today announced two upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place in National Harbor, Md., Nov. 5-9, 2025.

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform, today announced the appointment of Mauro Avanzi, M.D., Ph.D., as Chief Medical Officer. Dr. Avanzi is a Board-certified hematologist/oncologist, a physician-scientist and an immunologist with more than 15 years of clinical development experience across early and late stages. He will lead Dispatch’s clinical team to advance Dispatch’s growing pipeline of therapeutic candidates, with first-in-human studies planned for 2026.

Dispatch Bio announced its official launch today, with a mission to engineer a universal treatment across solid tumors, which represent approximately 90% of cancers worldwide.